These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26833657)

  • 61. Self-reactive antibodies associated with bronchiolitis obliterans syndrome subtype of chronic lung allograft dysfunction.
    Kaza V; Zhu C; Terada LS; Wang L; Torres F; Bollineni S; Mohanka M; Banga A; Joerns J; Mohanakumar T; Li QZ
    Hum Immunol; 2021 Jan; 82(1):25-35. PubMed ID: 33129576
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
    Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
    J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation.
    Hartwig MG; Snyder LD; Appel JZ; Cantu E; Lin SS; Palmer SM; Davis RD
    J Heart Lung Transplant; 2008 May; 27(5):547-53. PubMed ID: 18442722
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes.
    Raviv Y; D'Ovidio F; Pierre A; Chaparro C; Freeman M; Keshavjee S; Singer LG
    Clin Transplant; 2012; 26(1):133-42. PubMed ID: 22313020
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction immunosuppression strategies and outcomes post-lung transplant: A single center experience.
    Narula T; Alvarez F; Abdelmoneim Y; Erasmus D; Li Z; Elrefaei M
    Transpl Immunol; 2024 Aug; 85():102081. PubMed ID: 38986916
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients.
    Sweet SC; Armstrong B; Blatter J; Chin H; Conrad C; Goldfarb S; Hayes D; Heeger PS; Lyou V; Melicoff-Portillo E; Mohanakumar T; Odim J; Ravichandran R; Schecter M; Storch GA; Visner G; Williams NM; Danziger-Isakov L
    Am J Transplant; 2022 Jan; 22(1):230-244. PubMed ID: 34599540
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bronchiolitis obliterans syndrome development in lung transplantation patients.
    Parada MT; Alba A; Sepúlveda C
    Transplant Proc; 2010; 42(1):331-2. PubMed ID: 20172344
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lung transplantation in cystic fibrosis patients in Israel: The importance of ethnicity and nutritional status.
    Levine H; Prais D; Raviv Y; Rusanov V; Rosengarten D; Saute M; Hoshen M; Mussaffi H; Blau H; Kramer MR
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28886227
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alemtuzumab as compared to alternative contemporary induction regimens.
    LaMattina JC; Mezrich JD; Hofmann RM; Foley DP; D'Alessandro AM; Sollinger HW; Pirsch JD
    Transpl Int; 2012 May; 25(5):518-26. PubMed ID: 22394259
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of Forced Expiratory Volume in 1 Second (FEV1) and 6-Minute Walking Distance at 3, 6, and 12 Months and Annually on Survival and Occurrence of Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation.
    Fakhro M; Ingemansson R; Algotsson L; Lindstedt S
    Ann Transplant; 2017 Sep; 22():532-540. PubMed ID: 28871078
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?
    Verleden SE; Ruttens D; Vandermeulen E; Vaneylen A; Dupont LJ; Van Raemdonck DE; Verleden GM; Vanaudenaerde BM; Vos R
    Transplantation; 2013 May; 95(9):1167-72. PubMed ID: 23425818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.
    Li KHC; Ho JCS; Recaldin B; Gong M; Ho J; Li G; Liu T; Wu WKK; Wong MCS; Xia Y; Dong M; Tse G;
    Transplant Proc; 2018 Dec; 50(10):3723-3731. PubMed ID: 30577263
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome.
    Jain R; Hachem RR; Morrell MR; Trulock EP; Chakinala MM; Yusen RD; Huang HJ; Mohanakumar T; Patterson GA; Walter MJ
    J Heart Lung Transplant; 2010 May; 29(5):531-7. PubMed ID: 20133163
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
    Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
    J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation.
    Davis WA; Finlen Copeland CA; Todd JL; Snyder LD; Martissa JA; Palmer SM
    Am J Transplant; 2012 Mar; 12(3):745-52. PubMed ID: 22123337
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients.
    Dhillon GS; Valentine VG; Levitt J; Patel P; Gupta MR; Duncan SR; Seoane L; Weill D
    Clin Transplant; 2012; 26(1):105-10. PubMed ID: 21352378
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.
    Verleden SE; Vos R; Vandermeulen E; Ruttens D; Bellon H; Heigl T; Van Raemdonck DE; Verleden GM; Lama V; Ross BD; Galbán CJ; Vanaudenaerde BM
    Am J Transplant; 2016 Nov; 16(11):3262-3269. PubMed ID: 27367568
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
    Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
    Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.